CJC-1295 NO DAC + Ipamorelin Stack

CJC-1295 NO DAC + Ipamorelin is a dual-peptide combination studied for its complementary actions on growth hormone secretion. CJC-1295 NO DAC is a modified growth hormone-releasing hormone (GHRH) analogue that acts on the pituitary to stimulate GH synthesis and release. The absence of the Drug Affinity Complex (DAC) results in a shorter half-life, producing more physiologically representative pulsatile GH release in research protocols.

Ipamorelin is a pentapeptide that selectively activates the GHS-R1a receptor, mimicking the action of ghrelin without the appetite-stimulating or cortisol-elevating side effects observed with other GH secretagogues. Research has examined the combination for its effects on endocrine signalling, cellular IGF-1 pathways, and anabolic signalling cascades in laboratory models.

Composition

CJC-1295 NO DAC 5mg + Ipamorelin 5mg

Target

Growth hormone secretagogue receptors

Research Areas

Pulsatile GH release, endocrine modulation

CJC-1295 NO DAC

5mg per vial

Ipamorelin

5mg per vial

Total Dosage

10mg per vial

Receptor Targets

GHRH-R · GHS-R1a

GH Pathway

Pulsatile release model

Half-life (CJC)

~30 min (no DAC)

Half-life (Ipa)

~2 hours

1. 01CJC-1295 NO DACA GHRH analogue that stimulates pituitary growth hormone release. Without the DAC (Drug Affinity Complex), it produces pulsatile GH release more consistent with natural physiological patterns in research models.
2. 02IpamorelinA selective growth hormone secretagogue that mimics ghrelin's action at the GHS-R1a receptor. Research has examined its role in GH pulse amplitude and frequency without significant cortisol or prolactin effects.
3. 03Synergistic ActionThe combination targets two distinct GH release pathways simultaneously. Research investigates whether dual-pathway stimulation produces additive or synergistic GH release patterns compared to either peptide alone.